Teleflex (NYSE:TFX) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Teleflex (NYSE:TFX) from a sell rating to a hold rating in a research note released on Sunday morning.

Several other equities research analysts have also recently weighed in on TFX. UBS Group began coverage on Teleflex in a report on Tuesday, July 28th. They issued a “neutral” rating and a $145.00 price objective for the company. Royal Bank Of Canada raised Teleflex from a “sector perform” rating to an “outperform” rating and boosted their target price for the company from $135.00 to $155.00 in a research note on Friday, May 8th. Piper Sandler restated an “overweight” rating and set a $169.00 target price (up from $160.00) on shares of Teleflex in a report on Friday, August 7th. Bank of America raised Teleflex from an “underperform” rating to a “neutral” rating and set a $135.00 price target for the company in a research note on Monday, April 13th. Finally, Raymond James Financial reiterated an “outperform” rating and issued a $150.00 price target on shares of Teleflex in a report on Friday, May 8th. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Teleflex has a consensus rating of “Hold” and a consensus price target of $151.80.

Teleflex Stock Performance

Shares of NYSE:TFX opened at $133.66 on Friday. The company has a market cap of $5.66 billion, a price-to-earnings ratio of -5.74, a price-to-earnings-growth ratio of 0.88 and a beta of 0.81. The company has a 50-day moving average price of $131.99 and a 200-day moving average price of $123.12. The company has a current ratio of 2.60, a quick ratio of 2.12 and a debt-to-equity ratio of 0.94. Teleflex has a 12 month low of $100.18 and a 12 month high of $145.00.

Teleflex (NYSE:TFX) last posted its earnings results on Thursday, August 6th. The medical technology company reported $1.76 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.28 by $0.48. Teleflex had a positive return on equity of 11.93% and a negative net margin of 39.67%.The company had revenue of $570.33 million for the quarter, compared to analysts’ expectations of $559.59 million. During the same period last year, the firm earned $3.73 earnings per share. Teleflex’s quarterly revenue was up 28.9% on a year-over-year basis. Teleflex has set its FY 2026 guidance at 6.900-7.200 EPS. As a group, equities analysts anticipate that Teleflex will post 7.31 EPS for the current year.

Teleflex Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 30th. Shareholders of record on Friday, August 14th will be given a dividend of $0.34 per share. This represents a $1.36 annualized dividend and a yield of 1.0%. The ex-dividend date of this dividend is Friday, August 14th. Teleflex’s payout ratio is presently -5.84%.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Heartland Advisors Inc. purchased a new position in shares of Teleflex in the 2nd quarter valued at approximately $26,854,000. Allworth Financial LP purchased a new stake in Teleflex in the second quarter worth $44,000. NewEdge Wealth LLC purchased a new stake in Teleflex in the second quarter worth $531,000. Pzena Investment Management LLC bought a new position in Teleflex in the second quarter worth $76,462,000. Finally, BlackRock Inc. bought a new position in Teleflex in the second quarter worth $688,537,000. Institutional investors own 95.62% of the company’s stock.

About Teleflex

Teleflex Incorporated is a diversified global provider of medical technologies, specializing in critical care and surgery. Headquartered in Wayne, Pennsylvania, the company designs, manufactures and distributes devices and solutions used by healthcare professionals in hospital, ambulatory and alternate site settings. Teleflex focuses on delivering products that support complex interventional procedures and improve patient outcomes.

The company’s offerings span several key segments, including Interventional Urology, Respiratory & Anesthesia, Surgical, Cardiac Care, Vascular and Original Equipment Manufacturer (OEM) solutions.